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Abstract
Objectives
This case-control study was carried out to compare serum total 
antioxidant capacity (TAC) in the newly diagnosed children with 
epilepsy and that of a control group of healthy children at the same age 
and probable effects of antiseizure medications prescription on it.
Materials & Methods
Overall, 130 participants (65 in each group) aged between 1 and 17 
yr old were enrolled. The study was conducted in Children’s Medical 
Center, the Pediatrics Center of Excellence, Tehran, Iran in 2015. 
Serum TAC test was done for both control and patients group before 
antiseizure medications therapy and after 3 months of monotherapy 
with sodium valproate, carbamazepine and phenobarbital in 
patients. Serum TAC values were measured based on Erel’s method 
using an automated commercial kit. This method is based on the 
bleaching of the characteristic color of a more stable 2, 2’-azinobis- 
(3-ethylbenzothiazoline-6-sulfonic acid) radical cation by antioxidants. 
The results were expressed in mmol Trolox equivalent/l. 
Results
Serum TAC values were significantly lower in the patients group before 
drug administration [mean (SD): 1.31 (0.19) mmol/L] in comparison 
with the control group [mean (SD): 1.46 (0.21) mmol/L] (P<0.001). In 
the patient’s group, no differences were found in the serum TAC before 
and 3 months after antiseizure medications monotherapy.
Conclusion
Reduced serum TAC and an increased vulnerability to oxidative stress 
should be considered as an etiologic factor in the children with epilepsy.
Keywords: Total antioxidant capacity; Children; Epilepsy; antiseizure 
medications; Oxidative stress
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Introduction
Seizures and epileptic syndromes are common in 
children. 10.5 million children under 15 yr have 
active epilepsy. Seizures and epileptic syndromes 
have different mechanisms but recent studies had 
a new look to oxidative stress in pathogenesis 
of different epilepsies and other neurological 
disorders (1-3).  
Oxidative stress is a product of normal metabolism 
in the brain or abnormal insults to the brain, for 
example, brain hemorrhage. Brain tissue also 
produces a considerable amount of free oxygen 
and nitrogen radicals because of a large number of 
mitochondria. The brain also is vulnerable to free 
radical damage because of a considerable amount 
of oxidisable polyunsaturated fatty acids. (3)
Different antioxidative mechanisms work together 
to reduce oxidative stress in the brain. Nonenzymatic 
antioxidants including serum albumin, serum 
bilirubin and uric acid, vitamin E, and microelements 
(selenium) along with enzymatic antioxidative 
mechanisms including superoxide dismutase and 
glutathione peroxidase, are the main antioxidative 
mechanisms of the brain (4). 
Many antiepileptic drugs, including those widely 
used in epileptic patients, are metabolized to 
generate reactive metabolites having oxidative 
effects in the brain. Few studies have been 
performed in children to show the effects of 
anticonvulsants on the oxidative and antioxidative 
balance, in addition, in the majority of these studies, 
enzymatic antioxidants (glutathione peroxidase, 
superoxide dismutase, catalase, etc.) have been 
measured (5-8).
Serum concentrations of enzymatic antioxidants 
could be measured, but these measurements are 
time-consuming, expensive and require complex 
techniques, therefore, we carried out a study to 
measure serum total antioxidant capacity (TAC) 
with a more practical method in a group of children 
with newly diagnosed epilepsy before therapy and 
to compare this capacity by that of a group of age- 
and sex-matched healthy controls. 
Materials & Methods
Study design
We carried out this case-control study to compare 
serum TAC in children with newly diagnosed ep-
ilepsy (either outpatients or inpatients) and that 
of a group of sex- and age-matched healthy con-
trols. The effect of anticonvulsant monotherapy on 
the serum TAC also was studied in children with 
epilepsy before and 3 months after anticonvulsant 
monotherapy. The study was conducted in 
Children’s Medical Center, the Pediatrics Center 
of Excellence, as a major referral pediatric hospital 
of Tehran, Iran in 2010. 
Patients
To be enrolled, patients had to be less than 17 
yr old and had to meet the diagnostic criteria for 
idiopathic epilepsy. Seizures and epilepsies were 
classified according to the International League 
Against Epilepsy (9). A child Neurologist selected 
antiseizure medications according to the seizure 
type and the patient’s age. Phenobarbital, sodium 
valproate, and carbamazepine were administered 
as monotherapy. In the first group, 15 patients (7 
males and 8 females) were given phenobarbital 
monotherapy, in the second group, 26 patients (17 
males and 9 females) were administered sodium 
valproate monotherapy, and in the third group, 24 
patients (11 males and 13 females) received carba-
mazepine monotherapy. The patients who received 
anticonvulsants had been on the same drug at least 
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3 months and serum drug levels were at the ther-
apeutic level. Excluded cases were those children 
who had poor compliance and had been on chronic 
medication other than anticonvulsants. The control 
group was composed of healthy children less than 
17 yr seen in the Children’s Medical Center for 
routine vaccination, elective minor surgeries and 
routine monitoring for growth and development. 
For each patient, the following information was 
obtained; medical history and clinical examination 
with special emphasis on the age, sex, type, and 
frequency of seizures. 
The Ethics Committee of the Tehran University 
of Medical Sciences approved the study 
(no. 86-02-30-5635). Informed consent was 
obtained from the parents of all subjects studied. 
The study protocol conforms to the ethical 
guidelines of the 1975 Declaration of Helsinki as 
reflected in a priori approval by the institution\’s 
human research committee.
Blood sample collection
Blood samples were drawn by venipuncture from 
the antecubital vein using a disposal plastic syringe 
through a 23-gauge needle in the morning between 
8:00 and 11:00 am. Subjects fasted for 8 h before 
sample collection. All children with epilepsy were 
at least 24 h seizure-free before the sampling time. 
Samples were transferred to the laboratory within 
2 h for biochemical analysis. 
Biochemical analyses
Blood samples were centrifuged at 1500 × gr for 10 
min, and the serum was stored at -70 °C until the 
time of analysis. Serum total antioxidant capacity 
values were measured based on Erel’s method 
with an automated commercial kit (RANDOX 
total antioxidant status, RANDOX Laboratories 
Ltd. UK). This method is based on the suppression 
of the blue-green color of 2, 2’-azinobis-3-
ethylbenzothiazoline-6-sulfonic acid (ABTS) 
radical cation by antioxidants. The results were 
expressed in mmol Trolox equivalent/l (10). 
We also assessed serum albumin, total bilirubin, 
and uric acid as nonenzymatic antioxidants in 
each group. Albumin and uric acid were measured 
spectrophotometric method (using Bromocresol 
green and uricase reactant, respectively). Bilirubin 
was measured with dichloroaniline method. All 
spectrophotometric assays performed on Hitachi 
717 autoanalyzer.
Statistical analysis
A significant difference in the serum total 
antioxidant capacity between two groups was 
expected (power=80%, α=0.05, β=0.2). All data 
were reported as the means (SD). Categorical 
variables were analyzed by the χ2 -test. Continuous 
variables were analyzed by independent sample 
t-test, paired sample t-test, and One Way ANOVA 
on ranks with pairwise multiple comparison 
procedures (Dunn’s Method) when appropriate. A 
P<0.05 was considered significant. A biostatistician 
blinded to study groups performed the analysis.
Results
One hundred and thirty participants (65 in each 
group) aged 1 to 17 yr were enrolled in this study. 
Generalized tonic-clonic seizures consisted of 
50 cases (77%) and other seizure types were 8 
(12.3%) with complex partial seizures (CPS), 
4(6.1%) with simple partial seizure (SPS) and 3 
(4.6%) with atonic seizure. In the patient’s group, 
15 were given phenobarbital monotherapy, 26 
were given sodium valproate monotherapy, and 24 
received carbamazepine monotherapy. We found no 
significant differences between the groups regarding 
gender distribution or mean age (Table 1).
 Serum Total Antioxidant Capacity of Epileptic Children before and after Monotherapy with Sodium Valproate...
27Iran J Child Neurol. Summer 2018 Vol. 12 No. 3
The serum levels of total antioxidant capacity 
and nonenzymatic antioxidant parameter of the 
participants before AED administration are shown 
in Table 2. TAC was significantly lower in the 
patients with newly diagnosed epilepsy than that 
of the controls (P <0.001). Serum albumin and uric 
acid levels were not significantly different in the 
patients from the control, but serum total bilirubin 
was significantly lower in the patients with newly 
diagnosed epilepsy than that of the controls 
(P <0.001).
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Table 1. Baseline characteristics of the participants
Controls (n=65) pH (n=15) VPA (n=26) CBZ (n=24)
Age(yr)a,b 8.3 (3.8) 7.1 (3.2) 7.9 (3.3) 8.3 (3.6)
Sex (m/f) 39/26 7/8 17/9 11/13
Dosage, mg/kg/day NA 5-7 35-40 20-25
Abnormal EEG NA 8 12 10
Duration of treatment, 
months
NA 3 3 3
a; mean (SD). b; one-way ANOVA showed no significant difference between groups. n; number of participants.  PH; 
phenobarbital monotherapy group, VPA; sodium valproate monotherapy group, CBZ; carbamazepine monotherapy group. NA; 
not available. 
Table 2. Comparison of total antioxidant capacity and plasma level of nonenzymatic antioxidant 
parameter of the participants before anticonvulsant administration
Parameters Controls (n=65) Patients (n=65) P b
TAC, mmol Trolox equivalent/l 1.46 (0.21) 1.31 (0.19) <0.001
Albumin, mg/dl 5.22 (0.7) 5.1 (0.6) 0.199
Total bilirubin, mg/dl 0.51 (0.26) 0.29 (0.18) <0.001
Uric acid, mg/dl 3.7 (1.17) 3.91 (1.16) 0.171
a; Data are given as mean (SD), TAC; Total antioxidant capacity, n; number of participants, b; normality test (Shapiro-Wilk) 
failed and P by Mann-Whitney Rank Sum Test.
Three months after AED administration serum TAC 
and nonenzymatic antioxidant parameter again 
were measured in two groups. The total antioxidant 
capacity was significantly lower in the patients 
with newly diagnosed epilepsy who treated with 
sodium valproate and carbamazepine than that of 
the controls (P <0.05). Total antioxidant capacity 
had no significant difference between controls and 
who received phenobarbital. Serum albumin had 
no significant difference between controls and 
patients who treated with anticonvulsants after 3 
months. Serum total bilirubin and uric acid were 
significantly different in study groups (Table 3). 
There were also no significant differences in total 
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antioxidant capacity of the patients, before and 3 
months after anticonvulsant administration based 
on the treatment groups (Table 4).
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Table 3. Comparison of total antioxidant capacity and nonenzymatic antioxidant parameter of the controls 
and patients, 3 months after anticonvulsant administration
Parametera Controls (n=65) PH (n=15) VPA (n=26) CBZ (n=24)      P value
TAC, mmol Trolox 
equivalent/l 1.46 (0.21)
* 1.39 
(0.28) 1.24 (0.24)* 1.28 (0.19)*  <0.05
Albumin, mg/dl 5.22 (0.7) 5.14 (0.5) 4.74 (0.7) 4.69 (0.3) No difference
Total bilirubin, 
mg/dl 0.51 (0.26)
* 0.18 (0.11)* 0.36 (0.16)* 0.5 (0.01) <0.05
Uric acid, mg/dl 3.7 (1.17)* 5.02 (0.47)* 3.61 (0.39) 2.3 (0.21)* <0.05
a; Data are given as mean (SD), TAC; Total antioxidant capacity, n; number of participants,      
*; Pb < 0.05    b; One Way ANOVA on ranks with Pairwise Multiple Comparison Procedures (Dunn’s Method), PH; 
phenobarbital monotherapy group, VPA; sodium valproate monotherapy group, CBZ; carbamazepine monotherapy group
Table 4. Comparison of total antioxidant capacity of the patients, before and 3 months after 
anticonvulsant administration based on the treatment group
Total antioxidant capacitya 
Anticonvulsant Before treatment 3 months after treatment P b
Phenobarbital (n=15) 1.34 (0.18) 1.39 (0.28) 0.272
sodium valproate (n=26) 1.3 (0.21) 1.24 (0.24) 0.191
Carbamazepine (n=24) 1.26 (0.16) 1.28 (0.19) 0.701
n; number of patients. a; mmol Trolox equivalent/l, mean (SD). b; P value with paired sample t-test
Discussion
Serum TAC was significantly lower in children with 
newly diagnosed epilepsy before anticonvulsant 
initiation than that of the controls. Three months 
after receiving anticonvulsant monotherapy, 
serum total antioxidant capacity was significantly 
lower in children who received sodium valproate 
monotherapy and Carbamazepine monotherapy 
than that of the controls.
Excessive productions of free oxygen and nitrogen 
radicals and decreased antioxidant capacity, which 
result in membrane lipid peroxidation, have been 
implicated in the pathophysiology of neuronal hy-
perexcitability in the brain and seizure recurrence. 
Brain is rich in polyunsaturated fatty acids and 
has a high rate of oxidative metabolism with low 
antioxidant defense mechanism. Total antioxidant 
capacity of the organism includes enzymatic and 
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nonenzymatic endogenous antioxidant. These 
antioxidant systems scavenge free radicals of 
oxygen and nitrogen. Under certain conditions, the 
increase in oxidants and decrease in antioxidants 
cannot be prevented, and the oxidative/
antioxidative balance shifts towards the oxidative 
status. Antiepileptic drugs can increase lipid 
peroxidation by modulating antioxidant capacity, 
leading to seizure recurrence and therapeutic 
failure (11-13). 
Results of our study were in agreement with 
previous studies (4, 5, 14-17). Total antioxidant 
capacity was significantly reduced in untreated 
groups of adults with epilepsy in comparison 
to controls. There was also a marked reduction 
in total antioxidant capacity in the sodium 
valproate monotherapy groups compared to the 
carbamazepine monotherapy group (14). Our results 
were in accordance with that`s results, however, 
after 3 months of phenobarbital monotherapy no 
difference was found between controls and treated 
children with epilepsy. Moreover, in our study, 
children who received carbamazepine and sodium 
valproate monotherapy had significantly reduced 
total antioxidant capacity, 3 months after treatment, 
comparing to controls.
The serum total antioxidant capacity levels were 
lower in the untreated group comparing to controls. 
However, no significant difference was found in the 
serum total antioxidant capacity of sodium valproate, 
carbamazepine or phenobarbital monotherapy 
group and that of the controls (5). However, after 
treatment, serum total antioxidant capacity was 
significantly lower in children who received sodium 
valproate or carbamazepine. Both monotherapy 
and polytherapy did not change oxidative stress 
parameters in epileptic patients (14).
We also measured serum albumin, serum total 
bilirubin and uric acid in our participants. These 
are well-known endogenous antioxidant molecules 
in the serum (10). Uric acid concentrations were 
higher in untreated adults with epilepsy. There 
were also high uric acid concentrations in pa-
tients who treated with sodium valproate mono-
therapy(4). In our study, uric acid concentrations 
were significantly higher in children treated with 
phenobarbital than to the controls and other treat-
ment groups. We also found that in children who 
received carbamazepine, uric acid concentrations 
were significantly lower than to controls and sodi-
um valproate group.
The serum uric acid concentrations were lower in 
the sodium valproate monotherapy group than that 
of the untreated group. The serum bilirubin con-
centration was higher in the untreated epileptics 
than that of the controls, and albumin was lowt-
er in the sodium valproate group than that of the 
controls (5). In our study, serum albumin had no 
difference between treatment groups and controls. 
Moreover, serum total bilirubin was significantly 
higher in the controls than to sodium valproate and 
phenobarbital groups. We have no idea for these 
inconsistencies between our results and previous 
studies, but dietary habits and age of study popula-
tion could be an explanation for these differences.
Change in nonenzymatic antioxidant levels may be 
a protective mechanism against decreased total an-
tioxidant capacity (5, 16). However, our results did 
not support this hypothesis and nonenzymatic anti-
oxidants had no significant increased serum levels 
in our patients.
The results of our study must be interpreted in the 
face of certain limits. In this study, only serum 
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